Risk factors associated with mupirocin resistance in meticillin-resistant Staphylococcus aureus

Journal of Hospital Infection

Volumn 76, Issue 3, 2010, Pages 206-210

  Caffrey, A R ^a,b   Quilliam, B J ^b   LaPlante, K L ^a,b,c  

^a PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Meticillin resistant Staphylococcus aureus Mupirocin resistance; Risk factors

Indexed keywords

CEFEPIME; PSEUDOMONIC ACID;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PHARMACOEPIDEMIOLOGY; PREDICTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HOSPITALS, VETERANS; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUPIROCIN; RHODE ISLAND; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS;

EID: 77957684895     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2010.06.023     Document Type: Article

References (31)

1. Gorwitz R.J., Kruszon-Moran D., McAllister S.K., et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis 2008, 197:1226-1234.
2. Klein E., Smith D.L., Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 2007, 13:1840-1846.
3. Klevens R.M., Edwards J.R., Tenover F.C., McDonald L.C., Horan T., Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006, 42:389-391.
4. Muto C.A., Jernigan J.A., Ostrowsky B.E., et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003, 24:362-386.
5. Calfee D.P., Salgado C.D., Classen D., et al. Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Control Hosp Epidemiol 2008, 29(Suppl. 1):S62-80.
6. GlaxoSmithKline Mupirocin calcium ointment, 2% (Bactroban Nasal) package insert 2007, GlaxoSmithKline, Research Triangle Park, NC.
7. van Rijen M.M., Bonten M., Wenzel R.P., Kluytmans J.A. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: a systematic review. J Antimicrob Chemother 2008, 61:254-261.
8. Walker E.S., Vasquez J.E., Dula R., Bullock H., Sarubbi F.A. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective?. Infect Control Hosp Epidemiol 2003, 24:342-346.
9. Robicsek A., Beaumont J.L., Thomson R.B., Govindarajan G., Peterson L.R. Topical therapy for methicillin-resistant Staphylococcus aureus colonization: impact on infection risk. Infect Control Hosp Epidemiol 2009, 30:623-632.
10. Kallen A.J., Wilson C.T., Larson R.J. Perioperative intranasal mupirocin for the prevention of surgical-site infections: systematic review of the literature and meta-analysis. Infect Control Hosp Epidemiol 2005, 26:916-922.
11. Ammerlaan H.S., Kluytmans J.A., Wertheim H.F., Nouwen J.L., Bonten M.J. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis 2009, 48:922-930.
12. Cookson B.D., Lacey R.W., Noble W.C., Reeves D.S., Wise R., Redhead R.J. Mupirocin-resistant Staphylococcus aureus. Lancet 1990, 335:1095-1096.
13. Harbarth S., Dharan S., Liassine N., Herrault P., Auckenthaler R., Pittet D. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999, 43:1412-1416.
14. Simor A.E., Phillips E., McGeer A., et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 2007, 44:178-185.
15. Udo E.E., Jacob L.E., Mathew B. Genetic analysis of methicillin-resistant Staphylococcus aureus expressing high- and low-level mupirocin resistance. J Med Microbiol 2001, 50:909-915.
16. Yun H.J., Lee S.W., Yoon G.M., et al. Prevalence and mechanisms of low- and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. J Antimicrob Chemother 2003, 51:619-623.
17. Cookson B.D. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother 1998, 41:11-18.
18. Vasquez J.E., Walker E.S., Franzus B.W., Overbay B.K., Reagan D.R., Sarubbi F.A. The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans' Affairs hospital. Infect Control Hosp Epidemiol 2000, 21:459-464.
19. Jones J.C., Rogers T.J., Brookmeyer P., et al. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 2007, 45:541-547.
20. Simor A.E., Stuart T.L., Louie L., et al. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob Agents Chemother 2007, 51:3880-3886.
21. Park D.W., Kim M.J., Yang J.A., Jeong H.W., Sohn J.W., Chun B.C. Risk factors for isolation of low-level mupirocin-resistant versus -susceptible methicillin-resistant Staphylococcus aureus from patients in intensive care units. J Infect 2007, 54:337-342.
22. Clinical and Laboratory Standards Institute M100-S19: Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement 2009, CLSI, Wayne, PA.
23. Hosmer D.W., Lemeshow S. Applied logistic regression 2000, Wiley, New York, NY. 2nd edn.
24. Miller M.A., Dascal A., Portnoy J., Mendelson J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996, 17:811-813.
25. Walker E.S., Levy F., Shorman M., David G., Abdalla J., Sarubbi F.A. A decline in mupirocin resistance in methicillin-resistant Staphylococcus aureus accompanied administrative control of prescriptions. J Clin Microbiol 2004, 42:2792-2795.
26. Yanagisawa T., Kawakami M. How does Pseudomonas fluorescens avoid suicide from its antibiotic pseudomonic acid? Evidence for two evolutionarily distinct isoleucyl-tRNA synthetases conferring self-defense. J Biol Chem 2003, 278:25887-25894.
27. Sutherland R., Boon R.J., Griffin K.E., Masters P.J., Slocombe B., White A.R. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother 1985, 27:495-498.
28. Patel J.B., Gorwitz R.J., Jernigan J.A. Mupirocin resistance. Clin Infect Dis 2009, 49:935-941.
29. Ramsey M.A., Bradley S.F., Kauffman C.A., Morton T.M. Identification of chromosomal location of mupA gene, encoding low-level mupirocin resistance in staphylococcal isolates. Antimicrob Agents Chemother 1996, 40:2820-2823.
30. Driscoll D.G., Young C.L., Ochsner U.A. Transient loss of high-level mupirocin resistance in Staphylococcus aureus due to MupA polymorphism. Antimicrob Agents Chemother 2007, 51:2247-2248.
31. Elan Pharmaceuticals, Inc Cefepime hydrochloride (Maxipime) package insert 2007, Elan Pharmaceuticals, Inc., San Diego, CA.